ORBIMED ADVISORS LLC — 13F Holdings & Portfolio

CIK 1055951 · latest 13F-HR filed 2026-08-14

ORBIMED ADVISORS LLC manages $5.40B in 13F-reported U.S. long-equity assets across 129 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are EWTX (11.68%), ELVN (6.37%), LLY (5.73%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 35 new positions and exited 21; 52 existing positions rose in reported value and 22 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$5.40B

Long-equity book

Holdings
129

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+35 / −21 / ↑52 / ↓22

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 43%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Aug 18, 2026.

Assets Under Management
$20.61B
Discretionary
$20.61B
Employees
118
Accounts
32
Address
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
Phone
(212) 739-6400
Name Title / Status Ownership Type
ASHIYA, MONA ControlMEMBER
since Jul 2025
5–10%Individual
BLOCK III, SAM ControlCHIEF FINANCIAL OFFICER
since May 2019
Less than 5%Individual
BONITA, DAVID, PAUL ControlMEMBER
since Jan 2020
5–10%Individual
COON, DOUGLAS, W. ControlCHIEF COMPLIANCE OFFICER
since Feb 2016
Less than 5%Individual
COOPER, ALEXANDER, MATTHEW ControlGENERAL COUNSEL
since Jul 2010
Less than 5%Individual
GORDON, CARL, LEE ControlMEMBER
since Jan 1998
25–50%Individual
HSU, GEOFFREY, CHE-CHANG ControlMEMBER
since Jan 2010
10–25%Individual
NEILD, WILLIAM, CARTER ControlMEMBER
since Jan 2007
10–25%Individual
Rizzo, Matthew, Scott ControlMEMBER
since Jan 2022
5–10%Individual
STEVENS, CHARLES, SCOTLAND ControlMEMBER
since Apr 2019
5–10%Individual
Thompson, Peter, Armstrong ControlMEMBER
since Jan 2022
5–10%Individual
Ownership & leadership changes · 9 filings with changes since Mar 7, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Aug 3, 2026 filing
  • No longer listedBORHO, SVEN, HEINZ · MEMBER · 25–50% · control person · listed since Jan 1998
  • ChangedASHIYA, MONA · ownership Less than 5% → 5–10%
  • ChangedBONITA, DAVID, PAUL · ownership Less than 5% → 5–10%
  • ChangedHSU, GEOFFREY, CHE-CHANG · ownership 5–10% → 10–25%
  • ChangedRizzo, Matthew, Scott · ownership Less than 5% → 5–10%
  • ChangedSTEVENS, CHARLES, SCOTLAND · ownership Less than 5% → 5–10%
  • ChangedThompson, Peter, Armstrong · ownership Less than 5% → 5–10%
Jul 23, 2025 filing
  • AddedASHIYA, MONA · MEMBER · Less than 5% · control person
Jan 7, 2022 filing
  • No longer listedSILVERSTEIN, JONATHAN, TODD · MEMBER · 10–25% · control person · listed since Jan 2005
  • AddedRizzo, Matthew, Scott · MEMBER · Less than 5% · control person
  • AddedThompson, Peter, Armstrong · MEMBER · Less than 5% · control person
Feb 5, 2020 filing
  • AddedBONITA, DAVID, PAUL · MEMBER · Less than 5% · control person
May 23, 2019 filing
  • No longer listedSOTIRIOU, EVAN, DEAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Oct 2011
  • AddedBLOCK III, SAM · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ChangedHSU, GEOFFREY, CHE-CHANG · ownership 10–25% → 5–10%
  • ChangedSTEVENS, CHARLES, SCOTLAND · title EXECUTIVE OFFICER → MEMBER
Mar 29, 2019 filing
  • AddedSTEVENS, CHARLES, SCOTLAND · EXECUTIVE OFFICER · Less than 5% · control person
May 4, 2018 filing
  • No longer listedISALY, SAMUEL, DAVID · MANAGING MEMBER · 50–75% · control person · listed since Jan 1998
  • ChangedBORHO, SVEN, HEINZ · ownership 10–25% → 25–50%
  • ChangedGORDON, CARL, LEE · ownership 10–25% → 25–50%
  • ChangedHSU, GEOFFREY, CHE-CHANG · ownership Less than 5% → 10–25%
  • ChangedNEILD, WILLIAM, CARTER · ownership Less than 5% → 10–25%
  • ChangedSILVERSTEIN, JONATHAN, TODD · ownership 5–10% → 10–25%
Feb 23, 2016 filing
  • AddedCOON, DOUGLAS, W. · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedCOOPER, ALEXANDER, MATTHEW · title GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER → GENERAL COUNSEL
Mar 31, 2014 filing
  • No longer listedSHEFFERY, MICHAEL, BART · MEMBER · 5–10% · control person · listed since Jan 1998
Mar 7, 2012 filing (earliest on record)
  • ListedBORHO, SVEN, HEINZ · MEMBER · 10–25% · control person
  • ListedCOOPER, ALEXANDER, MATTHEW · GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ListedGORDON, CARL, LEE · MEMBER · 10–25% · control person
  • ListedHSU, GEOFFREY, CHE-CHANG · MEMBER · Less than 5% · control person
  • ListedISALY, SAMUEL, DAVID · MANAGING MEMBER · 50–75% · control person
  • ListedNEILD, WILLIAM, CARTER · MEMBER · Less than 5% · control person
  • ListedSHEFFERY, MICHAEL, BART · MEMBER · 5–10% · control person
  • ListedSILVERSTEIN, JONATHAN, TODD · MEMBER · 5–10% · control person
  • ListedSOTIRIOU, EVAN, DEAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

ORBIMED ADVISORS LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $630.5M 11.68% 15,518,492 SH
2 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $343.9M 6.37% 6,776,632 SH
3 ELI LILLY & CO LLY 532457108 $309.3M 5.73% 257,900 SH
4 MBX BIOSCIENCES INC MBX 55287L101 $189.3M 3.51% 3,428,736 SH
5 SINOVAC BIOTECH LTD SVA P8696W104 $184.5M 3.42% 2,718,735 SH
6 ASTRAZENECA PLC AZN G0593M107 $171.1M 3.17% 915,700 SH
7 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $118.6M 2.20% 2,209,400 SH
8 SIONNA THERAPEUTICS INC SION 829401108 $112.4M 2.08% 2,555,877 SH
9 CORVUS PHARMACEUTICALS INC CRVS 221015100 $107.0M 1.98% 7,165,006 SH
10 ARRIVENT BIOPHARMA INC AVBP 04272N102 $105.2M 1.95% 3,027,328 SH
11 GUARDANT HEALTH INC GH 40131M109 $87.6M 1.62% 583,700 SH
12 ARGENX SE ARGX 04016X101 $86.2M 1.60% 92,880 SH
13 MERCK & CO INC MRK 58933Y105 $85.2M 1.58% 663,400 SH
14 UNIQURE NV QURE N90064101 $83.3M 1.54% 1,807,486 SH
15 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $77.0M 1.43% 230,100 SH
16 EDWARDS LIFESCIENCES CORP EW 28176E108 $75.5M 1.40% 834,900 SH
17 PRELUDE THERAPEUTICS INC PRLD 74065P101 $73.2M 1.36% 13,724,571 SH
18 ABIVAX SA ABVX 00370M103 $72.8M 1.35% 546,522 SH
19 DYNE THERAPEUTICS INC DYN 26818M108 $71.9M 1.33% 3,235,684 SH
20 NATERA INC NTRA 632307104 $71.1M 1.32% 262,000 SH
21 CG ONCOLOGY INC CGON 156944100 $69.1M 1.28% 972,800 SH
22 UNITEDHEALTH GROUP INC UNH 91324P102 $67.0M 1.24% 161,100 SH
23 ARS PHARMACEUTICALS INC SPRY 82835W108 $66.4M 1.23% 8,288,510 SH
24 ASCENDIS PHARMA A/S ASND K08588103 $65.2M 1.21% 244,456 SH
25 HUMANA INC HUM 444859102 $65.2M 1.21% 164,100 SH
26 COGENT BIOSCIENCES INC COGT 19240Q201 $65.1M 1.21% 1,681,300 SH
27 BOSTON SCIENTIFIC CORP BSX 101137107 $63.3M 1.17% 1,483,200 SH
28 INTUITIVE SURGICAL INC ISRG 46120E602 $62.8M 1.16% 157,900 SH
29 MINERALYS THERAPEUTICS INC MLYS 603170101 $56.9M 1.05% 2,110,300 SH
30 ODYSSEY THERAPEUTICS INC ODTX 67613T104 $56.2M 1.04% 3,001,198 SH
31 XENON PHARMACEUTICALS INC XENE 98420N105 $53.9M 1.00% 892,471 SH
32 ARCUTIS BIOTHERAPEUTICS INC ARQT 03969K108 $53.5M 0.99% 2,042,000 SH
33 BRISTOL-MYERS SQUIBB CO BMY 110122108 $53.3M 0.99% 925,000 SH
34 Q32 BIO INC QTTB 746964105 $52.6M 0.97% 4,127,987 SH
35 STRYKER CORPORATION SYK 863667101 $50.1M 0.93% 159,100 SH
36 CARIS LIFE SCIENCES INC CAI 142152107 $50.0M 0.93% 2,806,811 SH
37 SPDR SERIES TRUST Put XBI 78464A870 $47.5M 0.88% 300,000 SH
38 THERMO FISHER SCIENTIFIC INC TMO 883556102 $45.5M 0.84% 90,700 SH
39 PALVELLA THERAPEUTICS INC NE PVLA 697947109 $44.7M 0.83% 292,360 SH
40 ELEVANCE HEALTH INC FORMERLY ELV 036752103 $44.4M 0.82% 114,700 SH
41 SHATTUCK LABS INC STTK 82024L103 $43.8M 0.81% 6,306,127 SH
42 UPSTREAM BIO INC UPB 91678A107 $39.4M 0.73% 5,693,589 SH
43 CRINETICS PHARMACEUTICALS IN CRNX 22663K107 $37.4M 0.69% 999,000 SH
44 RHYTHM PHARMACEUTICALS INC RYTM 76243J105 $35.9M 0.66% 322,900 SH
45 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $33.7M 0.62% 1,542,000 SH
46 FORTE BIOSCIENCES INC FBRX 34962G208 $33.5M 0.62% 1,577,705 SH
47 COMPASS THERAPEUTICS INC CMPX 20454B104 $33.3M 0.62% 15,219,994 SH
48 NEKTAR THERAPEUTICS NKTR 640268306 $32.5M 0.60% 465,346 SH
49 KRYSTAL BIOTECH INC KRYS 501147102 $30.9M 0.57% 83,200 SH
50 PRELUDE THERAPEUTICS INC WSDDF 000000000 $30.3M 0.56% 5,680,186 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $5.40B 129 0001172661-26-003740
2026-03-31 2026-05-15 $5.05B 114 0001172661-26-002369
2025-12-31 2026-02-17 $4.90B 108 0001172661-26-001119
2025-09-30 2025-11-14 $4.26B 110 0001172661-25-005047
Filer Information
Address
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
Phone
(212) 739-6400
Filing Manager
ORBIMED ADVISORS LLC
New York, NY
Signatory
Geoffrey C. Hsu
Member